Article

Intracorneal inlay now available in Canada

AcuFocus Inc. has received approval from Health Canada to market and sell the Kamra inlay, an innovative corneal inlay to treat presbyopia, within Canada.

Irvine, CA-AcuFocus Inc. (www.AcuFocus.com) announces that it has received approval from Health Canada to market and sell its corneal inlay for the treatment of presbyopia (Kamra) within Canada.

The company announced further that it has received a certificate of free sale, which will now open up additional markets, such as Argentina, Russian Federation, Venezuela, Peru, Mexico, India, and Colombia. The inlay is a unique treatment option that uses small-aperture optics to restore near and intermediate vision.

“We are excited to bring the [inlay] to surgeons in Canada so they can offer a sound solution to their [patients with presbyopia],” said Ed Peterson, AcuFocus president and chief executive officer. “We are striving to make the [inlay] available . . . around the world; with our CE Mark, certificate of free sale, and now approval from Health Canada . . . , we are one step closer to achieving that goal.”

To date, the inlay has been implanted in more than 15,000 patients and is now available in more than 40 countries worldwide. The inlay has received the CE Mark and is available in select markets across Europe, the Asia‐Pacific region, the Middle East, and South America. The company anticipates submitting for FDA Approval for distribution in the United States this year.

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.